In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer

[1]  A. Feuchtinger,et al.  In situ quantification of HER2–protein tyrosine kinase 6 (PTK6) protein–protein complexes in paraffin sections from breast cancer tissues , 2010, British Journal of Cancer.

[2]  C. Sotiriou,et al.  Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[3]  R. Prescott,et al.  Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Bartlett,et al.  Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer. , 2008, Biomarkers in medicine.

[5]  U. Landegren,et al.  Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. , 2008, Methods.

[6]  L. Goldstein,et al.  Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer , 2007 .

[7]  Hanlee P. Ji,et al.  Multiplexed protein detection by proximity ligation for cancer biomarker validation , 2007, Nature Methods.

[8]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[9]  M. Ellis,et al.  Can Molecular Markers Predict When to Implement Treatment With Aromatase Inhibitors in Invasive Breast Cancer , 2006 .

[10]  J. Bartlett,et al.  The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. , 2006, Cancer research.

[11]  T. Kirkegaard,et al.  Observer variation in immunohistochemical analysis of protein expression, time for a change? , 2006, Histopathology.

[12]  E. Tokunaga,et al.  Akt is frequently activated in HER2/neu‐positive breast cancers and associated with poor prognosis among hormone‐treated patients , 2006, International journal of cancer.

[13]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[14]  J. Bartlett,et al.  AKT activation predicts outcome in breast cancer patients treated with tamoxifen , 2005, The Journal of pathology.

[15]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[16]  J. R. Reeves,et al.  Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling , 2004, Breast Cancer Research.

[17]  K. Grigor,et al.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.

[18]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[20]  D. Lauffenburger,et al.  Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis , 2003, Journal of Biological Chemistry.

[21]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[22]  F. Maurer,et al.  The ErbB 2 ErbB 3 heterodimer functions as an oncogenic unit : ErbB 2 requires ErbB 3 to drive breast tumor cell proliferation , 2003, Nature Reviews Cancer.

[23]  U. Landegren,et al.  Protein detection using proximity-dependent DNA ligation assays , 2002, Nature Biotechnology.

[24]  J. Baselga,et al.  Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. , 2001, Journal of the National Cancer Institute.

[25]  J. R. Reeves,et al.  Evaluating HER2 amplification and overexpression in breast cancer , 2001, The Journal of pathology.

[26]  H. Wiley,et al.  ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors* , 1999, The Journal of Biological Chemistry.

[27]  S. Ethier,et al.  Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.